Oocyte maturation is a coordinated process that is tightly linked to reproductive potential. A better understanding of gene regulation during human oocyte maturation will not only answer an important question in biology, but also facilitate the development of in vitro maturation technology as a fertility treatment. We generated single-cell transcriptome and use previously published single-cell methylome data from human oocytes at different maturation stages to investigate how genes are regulated during oocyte maturation, focusing on the potential regulatory role of non-CG methylation.
INTRODUCTION
Proper development of the mature oocyte is an essential part of reproduction and the prerequisite for fertilization and downstream embryonic development. In humans, oocytes are arrested in prophase of meiosis I and remain quiescent until decades later when the follicles are recruited for growth 1 . Oocytes must mature and undergo transcription and physiological changes in preparation for ovulation and fertilization.
When the arrested prophase I oocyte (also known as germinal vesicle stage) is recruited to grow and mature, the germinal vesicle breaks down and the oocyte resumes meiosis I, leading to the intermediate maturation state metaphase I (MI stage).
As meiosis II progresses, the oocyte divides into a polar body and a mature metaphase II oocyte (MII stage). The MII oocyte is ready for ovulation and fertilization, and carries the maternal genome into the embryo after fertilization. The gene regulatory dynamics associated with oocytes maturation are of great interest to developmental biology and for clinical development of better in vitro maturation technology as a fertility treatment.
The transcriptomic landscape of oocyte development has been described in several mammalian species including cow, rabbit, rhesus, mouse and human 2,3 . Most of these studies, however either used microarray data or focus on only 2 stages of oocyte maturation, the germinal vesicle (GV) and the metaphase II oocyte (MII) 4 . From these studies we have learned that there are fewer transcripts in the MII oocyte which can be due to both reduced expression and RNA degradation 2,5 . Thousands of differentially expressed genes, both upregulated and downregulated, have been identified from GV to MII 2,5,6 . Further elucidation of gene regulatory mechanisms would help us understand the transcriptomic dynamics of oocyte maturation.
Similarly, previous DNA methylation studies on developing oocytes have provided great insight to the epigenomic landscape of the maturing oocyte. Mouse studies have shown that there is an overall increase in methylation as oocytes grow and mature 7, 8 . In humans, the process of DNA methylome erasure in primordial germ cells and in preimplantation embryos was recently shown in several genome-wide studies 9,10 . Our group published data in single-cell DNA methylome of human oocytes at various maturation stages last year, and demonstrated genome-wide increase in non-CG methylation as oocytes mature. Few previous study have investigated the epigenomic regulatory mechanisms that control differential gene expression during human oocyte maturation from GV to MII. The biological role of genome-wide non-CG methylation remodeling in the final stage of oocyte maturation remains to be investigated.
Most previously published human oocyte gene expression data either looks at only two timepoints, focuses their comparisons on MII versus in vitro matured oocytes, or focuses their comparison on oocyte versus early embryo 2,6,11-13 . Here we generated and correlated single-cell mRNA-seq and single-cell whole genome bisulfite sequencing data from the same individual cohort at three oocyte maturation stages (GV, MI, MII), in order to gain a better understanding gene regulation during human oocyte maturation through DNA methylation. We find that the accumulation of non-CG methylation in mature MII oocytes is accompanied by upregulation of the DNMT3B gene. There was a correlation between differentially methylated regions (DMRs) and gene expression with distal DMRs negatively correlating with gene expression and gene body DMRs positively correlating with gene expression. We identify transcription factors (TFs), ETS1 and YY1, which have binding motifs at DMRs and potentially direct DNMT3B methylation in the maturing oocyte genome. Many of the DMRs are located in the regulatory regions of the genome. These results suggest a regulatory role of non-CG methylation in transcriptomic changes during oocyte maturation.
RESULTS

Gene Expression, DEGs and Pathways
Oocytes were collected from 17 donors for single-cell transcriptome and single-cell DNA methylome (Table S1 ). Some of the oocytes were obtained from the same individuals.
In total, 21 mRNA-seq libraries were generated and analyzed together with previously published data on 32 whole genome bisulfite sequencing libraries 14 . For transcriptome data processing, mRNA sequencing reads were mapped to hg19 and Cufflinks 15 was used to calculate FPKM values. Individual samples were assessed for quality and uniformity based on their distribution of FPKM values (Figure S1A and S1B). We found high correlation between FPKM and normalized read count ( Figure S1C ) and therefore decided to continue all downstream analysis with FPKM values. We calculated the pairwise Pearson's correlation coefficient to assess intra-versus inter-individual variation ( Figure S1D ). Since we did not observe higher correlations between samples from the same individual compared to across individuals at the same oocyte maturation stage, we merged samples of the same stage and used the merged FPKM values for all 6 further analyses. We asked how similar the oocyte maturation stages were based on their transcriptome. Principal component analysis of the top 1000 expressed genes shows a clear separation between the immature GV/MI oocytes and the mature MII oocytes, with the GV and MI stages being almost indistinguishable from each other ( Figure 1A ). We next looked at how many expressed genes could be found in each maturation stage. We observed 15,224 GV, 13,283 MI and 10,892 MII expressed genes (FPKM >= 1; Figure 1B ). We asked how many genes were specific to each stage and found 427 GV, 3 MI and 7 MII specific genes. Such few cell-type specific genes in the later stages suggests that de novo transcription occurs in the earliest stage of oocyte maturation 16, 17 . All 4 zona pellucida glycoprotein genes (ZP1, ZP2, ZP3, and ZP4) were highly expressed in all three stages. We were also able to validate oocyte specific genes DAZL, GDF9, and BMP15 as being expressed and RBBP7 as significantly highly expressed in MII oocytes compared to MI (log 2 fold change 1.44; Figure S1E ). Some of the highest expressed genes in MII oocytes were PTTG1 and TUBB8. PTTG1 encodes a securin protein that prevents sister chromatid separation. TUBB8 encodes the betatubulin subunit primarily expressed in oocytes and the early embryo. Mutations in TUBB8 have been identified in infertile women with oocyte maturation arrest 18-20 . These genes have clear relevance and significance in oocyte maturation and development.
We used DESeq2 21 to calculate the number of differentially expressed genes (DEGs) between the three oocyte maturation stages. The largest number of DEGs was observed between the immature stages and MII ( Figure 1C ). There were 5,979 DEGs between GV and MII and 4,835 between MI and MII with an adjusted p-value of equal to 7 or less than 0.05. There were no significant DEGs between GV and MI, supporting the results of our PCA, that these two oocyte stages are very similar at the level of protein coding genes. This was also previously observed in microarray data on human oocytes 6, 17, 22 . In order to ensure our findings were not due to a bias in our analysis, we repeated the DEG analysis using a different program, edgeR 23 . Even though edgeR called fewer DEGs, there was a high overlap with those called by DESeq2 ( Figure S1F ).
Of the DEGs we identified using DESeq2, 1,362 were upregulated in MII compared to GV and 4,617 were downregulated. In the MII-to-MI pairwise comparison, 1,077 were upregulated and 3,758 were downregulated. We focused on the MII-to-MI DEGs as these two timepoints mark the transition from immature to mature oocyte (Table S2 ).
The upregulated genes fell into pathways involving RNA degradation, splicing and transport (Table 1) . Cell cycle, ubiquitin mediated proteolysis and oocyte meiosis were also significantly enriched pathways. These pathways are anticipated since genes involved in regulating meiosis should be expressed in the MII oocyte. Genes involved in pathways involving RNA dynamics are necessary given that: (1) the oocyte accumulates maternal RNAs necessary for early embryonic development, (2) there is slow maternal RNA degradation during oocyte maturation, as detected by the reduction in transcripts, and (3) maternal RNA degradation occurs shortly after fertilization. Downregulated pathways included various metabolic pathways including the TCA cycle and oxidative phosphorylation. We speculate that the downregulation of TCA and oxidative phosphorylation genes could be influenced by the underdeveloped mitochondria in oocytes 24,25 . 8 Of the genes most upregulated in mature MII oocytes we found SLX1B and MATN3 to be among the highest upregulated protein coding genes (log2 fold change 5.2 and 4.6 respectively). SLX1B encodes a protein that resolves DNA secondary structures that result from DNA repair or recombination, which we propose would be necessary for developing from MI to MII and completing meiosis post-fertilization. The MATN3 protein is a component of extracellular matrix which we hypothesize may be important in the development of oocyte extracellular structures. We queried our RNA-seq data for expression level of epigenetic regulators ( Figure S1G and Figure 1D ). TET3 is significantly upregulated in MII oocytes with a log2 fold change of 3.3x compared to MI oocytes. TET3 and TET2, which are expressed in all 3 stages of oocyte maturation, are important in removing methylation in the zygotic genome upon fertilization 26, 27 . DNMT1 is highly expressed in all 3 oocyte maturation stages and DNMT3B is significantly upregulated 2.8x in MII compared to MI oocytes. DNMT3A expression is reduced in MII and there is no detectable DNMT3L. The upregulation of DNMT3B led us to take a closer look at DNA methylation trends in the maturing oocyte.
DNA Methylation Correlates with Gene Expression in Oocytes
Global methylation trends for this cohort were previously described 14 . However, with the addition of transcriptomic data, we can investigate associations between DNA methylation and gene expression in oocytes. GV and MI stage oocytes had similar average methylation levels for cytosines in all contexts, CHG, CHH and CpG. We observed similar average CpG methylation levels across all three stages ( Figure S2A ).
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The non-CG average methylation level doubled in MII compared to the immature stages. The increase of non-CG methylation only in the MII stage coincides with the upregulation of DNMT3B in MII. Gene body methylation has been shown to be positively correlated with gene expression{Lister, 2009}. We asked if this same phenomenon can be observed in all three oocyte growth stages. There is a minor, but positive, correlation between gene body methylation and gene expression for all C contexts in all three stages (Figure 2A and Figure S2B ). This correlation is stronger for methylated CpGs, which have higher average methylation levels than non-CGs.
Differentially Methylated Regions Correlate with Gene Expression in Oocyte
Maturation
In order to further investigate methylation changes during oocyte maturation, we identified differentially methylated regions (DMRs) for each C context. We took differentially methylated regions from Yu et al., 2017, merged overlapping regions and used those for all downstream analysis. Only DMRs from the same stage oocyte were merged. DMRs have been proposed to be cis-regulatory elements in other cell types 28 , therefore we asked if the same could be true in the maturing oocyte. We counted over 70% of non-CG DMRs as distal, meaning not overlapping a gene promoter (-2kb to +500bp of gene TSS), exons or UTRs. All distal DMRs also had over 80% overlap with ENCODE DNaseI hypersensitivity sites (Table S3 ). The majority of DMRs were hypermethylated in the mature oocyte in the pairwise comparisons to the immature stages ( Figure 2B and Table S3 ). Hypermethylated DMRs in all genic context were associated with downregulation of gene expression in the MII-to-MI comparison (Figure 1 0 2C and Figure S2C ). However some hypermethylated CHH DMRs, specifically in introns and other exons, are associated with upregulated gene expression. In fact, 603 (60%) of the upregulated MII-to-MI DEGs have a DMR in their gene body. Further suggesting a role of DMRs in gene regulation at this stage of development.
DNMT3B binding partners and hypermethylation of gene targets
Of the DNMTs, only DNMT3B is upregulated as oocytes mature. DNMT3B is one of the de novo methyltransferases and can methylate non-CG motifs 29 . DNA methylation as a mechanism of gene regulation has been intensively studied in embryonic, germ and somatic cells. The upregulation of DNMT3B and increase of non-CG methylation could be necessary for several mechanisms in the developing oocyte. One potential mechanism could be to methylate the maternal genome in preparation for fertilization and embryo development. The second could be to regulate expression of oocyte genes during maturation. Many studies have examined this first point and looked at the epigenome from the MII oocyte through the beginning of embryogenesis 9,30 . We chose to focus on the second point.
In order to gain a better understanding of what factors may direct DNMT3B to methylate regions in the maturing oocyte genome, we looked for transcription factors (TF) that have been previously shown to directly bind DNMT3B via protein-protein binding array 31 ( Figure 3A ). Using the protein-protein binding data from Hervouet et al. 2009, we filtered for TFs that are expressed in oocytes ( Figure 3B ). Of the DNMT3B-TF binding partners 1 1 binding partners were significantly upregulated in MII compared to MI: ATF2, CREB1 and SP4. We next looked for transcription factor binding motifs in MII-to-MI distal DMRs (Table S4 ). We further filtered our list of expressed DNMT3B binding partners for factors that have their known motif in an MII distal DMR (denoted with * in Figure 3B ) and of those only ETS1 and YY1 were expressed in MII.
In a complementary approach, we ran our list of upregulated genes through ChIP Enrichment Analysis (ChEA) 32 which predicts regulatory TFs from a gene list ( Figure   3A ). ETS1 and YY1 were predicted to be regulatory TFs by ChEA with statistically significant enrichment scores (adjusted p-value 9.0*10 -4 and 2.9*10 -4 ; Figure 3C ).
Notably, we also found that ETS1 (ChEA adjusted p-value 5.3*10 -17 ) and YY1 (ENCODE TF ChIP-seq adjusted p-value 2.4*10 -21 ) were predicted to be regulatory TFs in the downregulated gene list as well. Therefore, we took a closer look at ETS1 and YY1 and their regulatory role in MII stage oocytes.
ETS1 is a transcription factor involved in many cellular processes including tumorigenesis and stem cell development. ETS family proteins are phosphorylated by MAP kinases and their activity as either an activator or repressor is modulated by cofactor binding 33 . YY1 is a ubiquitous transcription factor shown to have both activator and repressor activity 34, 35 . YY1 can interact with other proteins to stabilize enhancerpromoter loops 35, 36 . More importantly, YY1 is required for oocyte growth and follicular expansion 37 . Mice with a conditional knockout of YY1 are infertile and lack mature oocytes 37 . Using ChEA data, we identified the upregulated gene targets of ETS1 and 1 2 YY1 ( Figure 3D ). There were 123 gene targets of ETS1 and 117 gene targets of YY1 that were upregulated in MII compared to MI. Common GO Biological Processes between the two gene lists included mRNA processes, viral gene expression and protein targeting particularly to the ER. YY1 regulated genes were also involved in epigenetic regulation, specifically of histone H3 K9 methylation. Of the 603 MII upregulated genes that have a DMR in their gene body, 62 genes had an ETS1 binding site in their DMR and 151 genes had an YY1 binding site, with 60 genes in common between these two groups. Additionally, we found these gene body DMRs to be hypermethylated in 58 of the genes with ETS1 and 140 of the genes with YY1 binding sites. Therefore the gene body hypermethylation could be a result of ETS1 and YY1 directing DNMT3B to those genic regions.
LINE1 Elements at DMRs
Transposable elements (TEs) have been shown to function as regulatory elements and are expressed in oocyte 9,38-40 . Since TEs have been shown to be hypermethylated in MII oocytes compared to pre-implantation embryo 9 , we asked if there was differential methylation at TEs during oocyte maturation. We used TE coordinates from RepeatMasker to assess how many DMRs were at TE elements in the genome. Over 95% of DMRs, and over 98% of non-CG DMRs, were at transposable elements in the genome (Table S3 ). We focused further of LINE1 elements as those have been shown to be expressed in mammalian oocytes and early embryogenesis 40, 41 . We used GREAT to predict genes that were potentially regulated by the LINE1 elements in MII non-CG hypermethylated distal DMRs ( Figure S3 ). A number of terms were driven by the 1 5
Intragenic gene regulation via DNMT3B has been observed in other cell-types. For example mutations in DNMT3B occur in the majority of patients with Immunodeficiency, Centromere instability and Facial anomalies (ICF) syndrome. In these patients intragenic binding of DNMT3B was shown to affect expression of transcript isoforms{Gatto,2017}. Gene repression via DNMT3B-TF directed methylation has been observed in other cell types. Dnmt3B interacts with the repressor E2F6 to methylate promoters and silence germline genes in murine somatic tissues 44 . DNMT3B can also interact with PU.1 to methylate promoters of genes during monocyte to osteoclast differentiation 45 . DNMT3B recruitment to genomic loci may also alter the chromatin structure as DNMT3B has been shown to co-IP with HDAC1 and HDAC2 in human and mouse cell lines 46 . One of the TFs we identified in our study YY1, is essential for oocyte maturation and is known act as either an activator or repressor thru interaction with other regulatory proteins 35, 37 . Here we propose a model where DNMT3B recruitment by TFs, such as ETS1 and YY1, is responsible for targeted gene regulation in the MII oocyte.
Transposable element activity in germ cell and early embryonic development are widely studied 41, 47 . Previously it has been shown that LINE1 activity in GV oocytes is essential for progression to the MII stage 41 . Here we shown a clear example of how LINE1 elements may function as regulatory elements during oocyte maturation. LINE1 elements have previously been shown to be hypermethylated in gamete 9 thus this hypermethylation must occur during oocyte maturation from GV to MII. Overall this is an 1 6 example of how hypermethylation of regulatory elements can be used to control gene expression in the maturing oocyte.
Understanding the gene regulatory network in maturing oocytes could provide insight into the etiology of syndromes like oocyte maturation arrest 48 . By generating next generation sequencing data in three maturation timepoints we are providing a resource to the scientific community for further investigation into oocyte development.
MATERIALS AND METHODS
Oocyte collection
All human oocytes used in this study were obtained in embryology laboratories at Saint
Barnabas Center for Reproductive Medicine and Sher Institutes for Reproductive
Medicine under the regulatory oversight of Institutional Review Board (IRB)-approved Human Subjects protocol at each institution. After oocyte retrieval procedures under standard Assisted Reproductive Technology protocols, oocytes that were destined to be discarded were collected under previously obtained written informed consent. All consented materials were donated anonymously and carried no personal identifiers.
None of the oocytes was exposed to sperms or discarded due to fertilization or quality issues. GV and MI oocytes were collected at the time of maturity check. Most of the MII oocytes were collected from oocyte donors who had excess oocytes to dispose, due to rare circumstances that removed them from the donor list. 
Library preparation and mRNA-seq
From each single oocyte, cDNA was synthesized using SMART-Seq v4 ultra low input RNA kit (Clontech, cat # 634889). An mRNA-seq library was then prepared from each sample using standard Illumina TruSeq protocol. All libraries were multiplexed and sequenced on the same flow cell in order to minimize sequencing batch effect.
Sequencing was performed at the Epigenomics and Genomics Shared Facility at Albert Einstein College of Medicine.
Gene expression data analysis
The sequence data was aligned to the human genome build 19 using the STAR aligner with default parameters. Gene expression values were computed in FPKM units using 
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